The Academy of Managed Care Pharmacy (AMCP) supports scientifically sound research that compares the effectiveness and value of prescription drugs, as well as research aimed at tailoring treatment options to individual patients’ needs.
Government & Advocacy
AMCP advocates on behalf of managed care pharmacy professionals to ensure that their interests and the patients they serve are considered in federal and state health care policy decisions.
Featured Legislative & Regulatory Positions
See all Positions
AMCP supports the recognition of pharmacists as providers. When pharmacists are recognized as provider members of the health care team, patient outcomes improve, and patients report higher rates of satisfaction while overall health care costs are reduced. Recognized provider status would allow pharmacists to be reimbursed for providing health care services to patients. In a survey conducted in 2023 commissioned by Wolters Kluwer Health, 58% of Americans agreed that they are more likely to seek non-emergency medical care from a pharmacist.
AMCP supports increased access to Prescription Digital Therapeutics (PDTs). PDTs are software-based therapies that deliver clinical benefits to patients, either alone or in combination with other forms of treatment. These therapeutics require a prescription and are subject to oversight by the Food and Drug Administration (FDA). To be approved by the FDA, PDTs must demonstrate both safety and efficacy.
Featured Resources
See More Resources
Regulatory Updates
Letters, Statements, and Analysis
See All Letters, Statements, & Analysis
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services, the Department of Labor, and the Department of the Treasure (collectively, the Departments) for the opportunity to provide comments in response to the proposed rule titled “Enhancing Coverage of Preventive Services Under the Affordable Care Act [CMS 9887–P]” published in the Federal Register on October 28, 2024.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide feedback on the “Medicare $2 Drug List Model” issued by CMS.
On November 21, the New York Department of Financial Services (DFS) announced sweeping
market conduct regulations for pharmacy benefit managers (PBMs) serving health plans in the state. The DFS rule implements a landmark 2021 bill, S. 3762/A. 1396, which imposed restrictions on PBM contracts with health plans and pharmacies and established consumer
protections. This action follows previous DFS rulemaking that created a broad definition of
pharmacy benefit management services, required PBMs operating in the state to obtain a license, and established annual reporting requirements.
Latest NewsBREAKS
Explore Resources by Topic
Take Action
Grassroots Advocacy
AMCP represents managed care pharmacy in meetings with federal lawmakers and regulators and submits comments on proposed rules and regulations. We need and urge your participation in this process through our grassroots advocacy program.
